← Issue №18/ week of Nov 1, 2026/IBD

The impact of normalization of histology on disease course in microscopic colitis: a retrospective cohort study.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD retrospective · n=380 · Nov 1, 2026 · Inflamm Bowel Dis · IF 4.5

The impact of normalization of histology on disease course in microscopic colitis: a retrospective cohort study.

New evidencebiomarkerepidemiology
Clinical takeawayRetrospective evidence suggests histologic normalization may be a potential treatment target in MC, particularly for symptomatic patients, to reduce corticosteroid use. Further studies are needed to confirm this as a clinical goal.
What it foundHistologic normalization at first repeat colonoscopy reduced corticosteroid use (OR 0.26; 0.13-0.53) compared to patients with persistent MC changes, especially symptomatic ones (OR 0.22; 0.08-0.59), though the effect was weaker in asymptomatic patients (OR 0.45; 0.16-1.29).
ContextChallenges the lack of consensus on treatment goals in MC by suggesting histologic remission as a potential target to reduce corticosteroid use, based on retrospective cohort data.
Emergingsuggested applicable standard· United European Gastroenterology (UEG) & European Microscopic Colitis Group (EMCG), "European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations" (Miehlke et al.), 2021, Recommendation 1.8

Decision at stakewhether histologic normalization should be a treatment target in microscopic colitis

Diagnose microscopic colitis on colonoscopy with biopsies from at least two colonic segments (proximal/ascending and distal/descending, ~3 biopsies per segment in separate jars, avoiding rectum-only sampling since it can miss >20% of cases), plus celiac serology (tTG-IgA) and an infectious workup before treatment. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose microscopic colitis on colonoscopy with biopsies from at least two colonic segments (proximal/ascending and distal/descending, ~3 biopsies per segment in separate jars, avoiding rectum-only sampling since it can miss >20% of cases), plus celiac serology (tTG-IgA) and an infectious workup before treatment. First step is withdrawal of implicated drugs (PPIs, NSAIDs, SSRIs, and other suspected culprits such as statins/ARBs), but only for agents with a suspected chronological (temporal) relationship between drug introduction and onset of diarrhea, and only when discontinuation is clinically safe and an appropriate alternative exists, rather than reflexive class-wide withdrawal (the European UEG/EMCG guideline suggests considering withdrawal of any drug with such a temporal relationship, and notes PPI-switch data contradict a strict class effect), together with smoking-cessation counseling. For symptomatic disease, AGA's guideline recommends budesonide 9 mg once daily for 6-8 weeks as induction, preferred over mesalamine (budesonide gave nearly double the remission rate in head-to-head RCTs); when budesonide is not feasible AGA suggests mesalamine, bismuth subsalicylate, or prednisone/prednisolone as second-line alternatives, the European UEG/EMCG guideline is stricter and recommends against mesalamine outright (not superior to placebo in trials). Maintenance uses budesonide tapered to the lowest effective dose (typically 4.5-6 mg/day) individualized to the patient, since roughly 80% relapse after stopping. Budesonide non-/partial responders should be evaluated for bile acid diarrhea (cholestyramine trial can reduce budesonide dependence), celiac disease, and SIBO before escalating refractory disease to thiopurines (azathioprine/6-MP) or biologics (anti-TNF, vedolizumab).

United European Gastroenterology (UEG) & European Microscopic Colitis Group (EMCG), "European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations" (Miehlke et al.), 2021, Recommendation 1.8 · reviewed 2026-07-23 ↗
Kizza-Brown JFN, Ananthakrishnan AN · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues